Mirtazapine Arrow Generiques

Mirtazapine, the active ingredient in Mirtazapine Arrow Generiques, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral dosage form for oral use. It is prescribed for the treatment of major depressive disorder in adult patients and works by enhancing norepinephrine and serotonin transmission, helping to improve mood, sleep and appetite.

GNH USA supplies Mirtazapine Arrow Generiques as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU regulatory standards and is manufactured under GMP conditions.

Mirtazapine is used primarily within the antidepressant therapeutic class to treat depressive disorders.

- Major depressive disorder: reduces core depressive symptoms and improves functional outcomes. - Depressive episodes: alleviates mood disturbances and associated insomnia. - Treatment‑resistant depression (adjunct): may be added when first‑line antidepressants are insufficient.

Mirtazapine may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Drowsiness or sedation - Increased appetite leading to weight gain - Dry mouth - Constipation

Serious or Rare Side Effects: - Agranulocytosis - Severe neutropenia - Hepatotoxicity

When prescribing mirtazapine, clinicians should consider several safety precautions.

- Assess psychiatric history: monitor for worsening depression or emergence of suicidal thoughts. - Evaluate hepatic function: adjust use in patients with significant liver impairment. - Review concomitant CNS depressants: avoid excessive sedation when combined. - Caution in elderly: increased risk of falls due to sedation and orthostatic hypotension. - Pregnancy and lactation: use only if potential benefit outweighs risk, as safety data are limited. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture.

Mirtazapine can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome; a washout period is required. - Potent CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine plasma levels. - CNS depressants (e.g., benzodiazepines, alcohol): can cause profound sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): monitor for additive serotonergic effects. - Antihistamines: may enhance sedation. - Diuretics: monitor blood pressure due to possible additive hypotensive effect.